Mirtazapine: A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression

CNS Drugs

Volumn 5, Issue 5, 1996, Pages 389-402

  Davis, Rick ^a   Wilde, Michelle I ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CLOMIPRAMINE; DOXEPIN; MIRTAZAPINE; TRAZODONE;

CONSTIPATION; DEPRESSION; DROWSINESS; DRUG THERAPY; EYE TOXICITY; HEART PALPITATION; HUMAN; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; TREMOR; VERTIGO; XEROSTOMIA;

EID: 0029953756     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605050-00007     Document Type: Review

References (49)

1. Sitsen JMA, Zivkov M. Mirtazapine: clinical profile. CNS Drugs 1995; 4 Suppl. 1: 39-48
2. O'Connor WT, Leonard BE. Effect of chronic administration of the 6-aza analogue of mianserin (Org. 3770) and its enantiomers on behaviour and changes in noradrenaline metabolism of olfactory-bulbectomized rats in the 'open field' apparatus. Neuropharmacology 1986 Mar; 25: 267-70
3. Andrews JS, Hansen JHM, Linders S, et al. Effects of imipramine and mirtazapine on operant performance in rats. Drug Dev Res 1994 May; 32: 58-66
4. Ruigt GSF, van Proosdij JN. Antidepressant characteristics of Org 3770, Org 4428 and Org 9768 on rat sleep [abstract]. Eur J Pharmacol 1990 Jul; 183: 1467-8
5. 1A-mediated serotonergic neurotransmission. CNS Drugs 1995; 4 Suppl. 1: 29-38
6. de Boer TH, Maura G, Raiteri M, et al. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 1988 Apr; 27: 399-408
7. 1-Adrenoreceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur J Pharmacol 1994; 261: 59-64
8. Clement H-W, Gemsa D, Wesemann W. The effect of adrenergic drugs on serotonin metabolism in the nucleus raphe dorsalis of the rat, studied by in vivo voltammetry. Eur J Pharmacol 1992; 217: 43-8
9. 2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo. Eur J Pharmacol 1994 Feb 21; 253: R5-6
10. 2-adrenoceptor blockade in the central nervous system and the effects of the enantiomers of mianserin and its aza-analog ORG 3770. Arch Int Pharmacodyn Ther 1988 Jan-Feb; 291: 185-201
11. 1A-agonist 8-OHDPAT. Psychopharmacology 1993; 112: 121-8
12. 2A receptors after chronic treatment with remeron. Eur Neuropsychopharmacol. In press
13. 3 receptors in cultured mouse neuroblastoma cells. Neuropharmacology 1994 Mar-Apr; 33: 501-7
14. Berendsen HHG, Jenck F, Broekkamp CLE. Selective activation of 5-HT1A receptors induces lower lip retraction in the rat. Pharmacol Biochem Behav 1989; 33: 821-7
15. Berendsen HHG, Broekkamp CLE. Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br J Pharmacol 1990; 101: 667-73
16. Mongeau R, Blier P, de Montigny C. In vivo electrophysiological evidence for tonic activation by endogeneous noradrenaline on α2-adrenergic heteroreceptors of 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 1993; 347: 266-72
17. de Montigny C, Haddjeri N, Mongeau R, et al. The effects of mirtazapine on the interactions between central noradrenergic and serotonergic systems. CNS Drugs 1995; 4 Suppl. 1: 13-7
18. Leonard BE. Mechanisms of action of antidepressants. CNS Drugs 1995; 4 Suppl. 1: 1-12
19. Voortman G, Paanakker JE. Bioavailability of mirtazapine from Remeron (Rm) tablets after single and multiple oral dosing. Hum Psychopharmacol 1995 Jul: 10 Suppl. 2: S83-96
20. Timmer CJ, Lohmann AAM, Mink CPA. Pharmacokinetic dose-proportionality study at steady state of mirtazapine from Remeron (Rm) tablets. Hum Psychopharmacol 1995 Jul; 10 Suppl. 2: S97-106
21. Murdoch DL, Ashgar J, Ankier SI, et al. Influence of hepatic impairment on the pharmacokinetics of single doses of mirtazapine in elderly subjects [abstract]. Br J Clin Pharmacol 1943 Jan; 35: 76P
22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed, Washington, DC: American Psychiatric Association, 1980
23. Halikas JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol 1995 Jul; 10 Suppl. 2: S125-33
24. Smith WT, Glaudin V, Panagides J, Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1490; 26 (2): 191-6
25. Khan MC. A randomised, double-blind, placebo-controlled, 5-weeks' study of Org 3770 (mirtazapine) in major depression. Hum Psychopharmacol 1995 Jul; 10 Suppl. 2: S119-24
26. Claghorn JL, Lesem MD. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995 Jun 8; 34: 165-71
27. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1945; 56: 519-25
28. Vartiainen H, Leinonen K. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Kur Neuropsychopharmacol 1994 Jun; 4: 145-50
29. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Psychopharmacol 1995; 10 Suppl. 4: 25-35
30. Zivkov M, Roes KCB, Pols AG. Efficacy of Org 3770 (mirtazapine) vs amitriptyline in patients with major depressive disorder: a meta-analysis. Hum Psychopharmacol 1995 Jul; 10 Suppl. 2: S135-45
31. Zivkov M, De Jongh GD. Org 3770 versus amitriptyline: a 6-week randomised double-blind multicentre trial in hospitalized depressed patients. Hum Psychopharmacol 1995 May-Jun; 10: 173-80
32. Richou H, Ruimy P, Charbaut J, et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum Psychopharmacol 1995 Jul-Aug; 10: 263-71
33. Marttila M, Jääskeläinen J, Järvi R, et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol 1945; 5: 441-6
34. van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995 Mar; 10: 3-9
35. Montgomery SA. Safery of mirtazapine: a review. Int Clin Psychopharmacol 1995; 10 Suppl. 4: 37-45
36. Organon Remeron is first alpla-2 receptor antagonist antidepressant recommended by advisory committee; labeling should note neutropenia risk. FDC Rep Pink Sheet 1995 Oct; 23: 16
37. FDA panel clears Organon's Remeron. Scrip 1995 Oct 24; 2071: 20
38. N.V. Organon. Mirtazapine prescribing information. Oss. The Netherlands; N.V. Organon, 1995
39. Mattila M, Mattila MJ, Vrijmoed-de Vries M, et al. Actions and interactions of psychotropic drugs on human performance and mood: single doses of ORG 3770, amitriptyline, and diazepam. Pharmacol Toxicol 1989 Aug; 65: 81-8
40. Langsdale T. WHO Collaborative Study on Psychological Problems in General Health Care: hidden burden of mental illness uncovered by World Health Organisation study. Pharmaco-resources 1995; 26: 9
41. Goldblatt MJ, Schatzberg AF. Does treatment with antidepressant medication increase suicidal behavior? Int Clin Psychopharmacol 1991; 6: 219-26
42. Lehmann HE, Fenton FR, Deutsch M, et al. An 11-year follow-up study of 110 depressed patients. Acta Psychiatr Scand 1988; 78: 57-65
43. Kiloh LG, Andrews G, Neilson M. The long-term outcome of depressive illness. Br J Psychiatry 1989; 153: 752-7
44. Lee AS, Murray RM. The long-term outcome of Maudsley depressives. Br J Psychiatry 1991; 153: 741-51
45. Katon W, Schulberg H. Epidemiology of depression in primary care. Gen Hosp Psychiatry 1992; 14: 237-47
46. Rush AJ, Trivedi M, Schriger D, et al. The development of clinical practice guidelines for the diagnosis and treatment of depression. Gen Hosp Psychiatry 1992; 14: 230-6
47. Wells KB, Katon W, Rogers B, et al. Use of minor tranquilizers and antidepressant medications by depressed outpatients: results from the Medical Outcomes Study. Am J Psychiatry 1994; 151: 694-700
48. Hall RCW, Wise MG. The clinical and financial burden of mood disorders: cost and outcome. Psychosomatics 1995; 36 Suppl.: S11-8
49. Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993; 7: 191-5